Understanding Amyotrophic Lateral Sclerosis (ALS): Causes, Symptoms, and Treatments

Amyotrophic Lateral Sclerosis (ALS)

Overview

Amyotrophic lateral sclerosis (ALS) is a type of neurodegenerative disorder that falls under the broader category of motor neuron diseases. This progressive disease targets the nerve cells responsible for voluntary muscle movement, which includes functions such as chewing, walking, and talking. Currently, there is no cure for ALS, and symptoms tend to worsen over time.

Individuals diagnosed with ALS are typically between the ages of 40 and 70, although it can occur in younger people as well. The disease is global and does not discriminate based on socioeconomic status, race, or ethnicity. In the United States, approximately 30,000 individuals are affected by ALS, with around 5,000 new cases reported annually.

Pathophysiology

ALS is characterized by the progressive degeneration and death of motor neurons, which are essential for transmitting signals between the brain, spinal cord, and muscles. These neurons facilitate voluntary movement by relaying messages from upper motor neurons in the brain to lower motor neurons in the spinal cord, which then communicate with muscles throughout the body.

In patients with ALS, both upper and lower motor neurons deteriorate, leading to impaired muscle function. This degeneration results in muscle weakness, twitching, and atrophy, ultimately causing a complete loss of voluntary movement control. The exact causes of ALS remain unclear, although genetic and environmental factors may contribute to its development.

Symptoms

Early symptoms of ALS may include:

– Muscle twitches in the arms, legs, shoulders, or tongue
– Muscle cramps
– Tight and stiff muscles
– Weakness in an arm, leg, neck, or lungs
– Slurred or nasal speech
– Difficulty chewing or swallowing

In some cases, symptoms may first manifest in the hands, making simple tasks like buttoning a shirt or turning a key challenging. For others, symptoms may begin in a leg, leading to difficulties in walking or running. When symptoms initiate in the limbs, it is referred to as “limb onset.” Conversely, if issues with speech and swallowing arise first, it is termed “bulbar onset.”

Regardless of how symptoms present, ALS progresses, causing muscle weakness and atrophy to spread throughout the body. Eventually, individuals face challenges with movement, swallowing, speaking, and breathing. The difficulties associated with chewing and swallowing increase the risk of choking, while the accelerated calorie burn in ALS patients can lead to rapid weight loss and malnutrition.

Despite the physical challenges, cognitive functions such as reasoning, memory, and understanding often remain intact, leaving patients aware of their declining physical capabilities, which can lead to anxiety and depression. As respiratory muscles weaken, individuals may lose the ability to breathe independently and require ventilatory support, increasing their risk of pneumonia. Additionally, some individuals may experience cramps or painful nerve damage.

Diagnosis

Diagnosing ALS does not involve a single definitive test. Instead, physicians rely on a comprehensive evaluation of the patient’s signs and symptoms through a physical examination. Various tests may be conducted to rule out other conditions that exhibit similar symptoms, such as HIV or human T-cell leukemia virus. The presence of symptoms related to both upper and lower motor neurons typically suggests ALS.

Treatments and Management

Currently, there is no cure for ALS, and treatment focuses on supportive care provided by multidisciplinary teams. The goal of this care is to manage symptoms, reduce risks, and enhance the patient’s quality of life. The teams typically include physicians, pharmacists, physical and occupational therapists, speech therapists, nutritionists, social workers, respiratory therapists, clinical psychologists, and hospice nurses. Together, they develop tailored treatment plans and provide necessary equipment.

The American Academy of Neurology recommends the following management strategies for ALS:

– Administer riluzole to all ALS patients to help reduce nerve cell damage, though it does not reverse existing damage.
– Utilize edaravone, an FDA-approved drug that may slow the decline in daily functioning among ALS patients.
– Consider feeding patients through a PEG (percutaneous endoscopic gastrostomy) to maintain their nutritional status and body weight.
– Implement non-invasive ventilation for patients with inadequate respiratory function to prolong survival.
– Employ mechanical insufflation/exsufflation devices to clear mucus from patients’ airways.
– Evaluate the need for invasive ventilator support in patients experiencing respiratory failure while remaining mentally competent.
– Consider muscle relaxants for patients with spasticity.
– Evaluate the use of anticholinergics and sympathomimetics for hypersalivation, as well as mucolytics for thick secretions.
– Prescribe lorazepam for anxiety and selective serotonin reuptake inhibitors (SSRIs) for depression.
– Utilize NSAIDs, tramadol, ketorolac, morphine, or transdermal fentanyl for pain management.

References

Armon, C. 2018. Amyotrophic Lateral Sclerosis. [Online]. [28 August 2018]. Available from: https://emedicine.medscape.com/article/1170097-overview
National Institute of Neurological Disorders and Stroke. 2018. Amyotrophic Lateral Sclerosis (ALS) Factsheet. [Online]. [28 August 2018]. Available from: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet
John Hopkins Medicine. ALS – Amyotrophic Lateral Sclerosis. [Online]. [28 August 2018]. Available from: https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html